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Abstract
Introduction—Receipt of hepatitis C virus (HCV) RNA testing following a positive HCV 
antibody (anti-HCV+) test result to establish current infection is a quality indicator for HCV-
related care. This study examines HIV infection status as a predictor of HCV RNA test receipt 
after an anti-HCV+ result in the primary care setting.
Methods—Electronic medical records of anti-HCV+ patients from a multisite retrospective study 
of patients aged ≥18 years who utilized one or more primary care outpatient services during 2005–
2010 were analyzed in 2014. A multivariable logistic regression model examined the independent 
relationships between patient characteristics and receipt of HCV RNA testing.
Results—Among 1,115 anti-HCV+ patients, 133 (11.9%) were also HIV-positive. Of these, 
77.4% (n=103) underwent HCV RNA testing to determine current infection status. By contrast, 
66.7% (n=654/980) of anti-HCV+ patients who were HIV-negative received HCV RNA testing. 
Following multivariable adjustment, the odds of receiving HCV RNA testing were higher among 
anti-HCV+ patients who were also HIV-positive (AOR=1.9, 95% CI=1.2, 3.0), compared with 
their HIV-negative counterparts. Elevated alanine aminotransferase level was also associated with 
receipt of HCV RNA testing (AOR=1.9, 95% CI=1.4, 2.4). Black race was associated with 
decreased odds of receiving HCV RNA testing (AOR=0.7, 95% CI=0.5, 1.0).
Conclusions—HIV infection status is independently associated with the likelihood of receiving 
HCV RNA testing following an anti-HCV+ result. One quarter of anti-HCV+ patients who were 
also HIV-positive and one third of their HIV-negative counterparts, respectively, did not receive 
testing to establish active HCV infection, which is imperative for appropriate care and treatment.
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An estimated 3.2 million people in the U.S. are currently infected with hepatitis C virus 
(HCV).1,2 Approximately 10%–15% of those identified with HCV in the U.S. are also 
infected with HIV.1,3–5 Individuals with HCV infection are at an elevated risk for cirrhosis, 
hepatocellular carcinoma (HCC), liver transplantation, and death.6–9 HCV co-infection with 
HIV can exacerbate the expected natural history of HCV,10–12 complicating management 
and treatment regimens, and accelerating progression to fibrosis, cirrhosis, and HCC.13–15
Antiviral treatment for HCV has been demonstrated to be effective among HCV/HIV co-
infected people and can be used safely in concert with HIV antiretroviral therapy.16 The 
benefits of HCV treatment, such as regression of liver fibrosis and decreased mortality, are 
observed in both mono- and co-infected individuals.11
Despite guidance for the management and treatment of people who are co-infected with HIV 
and HCV,17–19 many do not receive the recommended quality of care,16 and therefore are 
unable to initiate treatment or manage their infection, and experience a lower quality of 
life.20,21 CDC recommends that all individuals who test positive for HCV antibodies (anti-
HCV+) receive HCV RNA testing to establish current infection and facilitate receipt of 
appropriate care and treatment.20,22 However, studies show that 24%–39% of patients do not 
receive HCV RNA testing after an anti-HCV+ test result.22–25 Moreover, HCV/HIV co-
infection is associated with greater odds of receiving high-quality care (e.g., receipt of HCV 
RNA testing for diagnosis of HCV viremia) than HCV infection alone.22 A post hoc cross-
sectional analysis was performed to examine HIV infection status as an independent 




Electronic medical record (EMR) data of anti-HCV+ patients identified from the BEST-C 
Retrospective Cohort Study26 was used; BEST-C was designed to examine HCV testing and 
prevalence in four large health centers in the U.S.26,27 Data collection was based on review 
of EMR data for new patients aged ≥18 years utilizing one or more primary care outpatient 
services between January 2005 and December 2010, who had no previous diagnosis of HCV 
infection. Of 209,076 patients in the cohort, 17,464 were tested for anti-HCV.26 The current 
analysis was restricted to 1,115 anti-HCV+ patients.
Measures
The outcome measure was receipt of HCV RNA testing. HCV RNA testing was defined as 
receipt of HCV RNA testing following an anti-HCV+ test result. Independent patient 
characteristics examined included birth year, race/ethnicity, gender, marital status, history of 
injection drug use (IDU), history of elevated levels of alanine aminotransferase (ALT), and 
HIV infection status. HCV genotyping was also explored. (Definitions for IDU, ALT, and 
HIV infection are provided elsewhere.26) HCV genotyping data were derived from EMR 
laboratory data.
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Mean frequencies and percentages were calculated to describe the characteristics of the 
analytic population. A multivariable logistic regression model was fit to examine 
independent relationships between receipt of HCV RNA testing (dependent variable) and 
patient characteristics (HIV infection status, birth year, gender, marital status, race/ethnicity, 
history of IDU, and history of elevated ALT level, controlling for total number of visits). 
Statistical significance was set at a two-tailed p-value of 0.05. Data were analyzed using 
SUDAAN, version 11.0.0 and SAS, version 9.3; analyses were completed in 2014.
Results
Table 1 shows the characteristics of the 1,115 anti-HCV+ patients included in this analysis. 
Of these, 757 (67.9%) received HCV RNA testing to establish infection, of which 550 
(72.6%) had positive results. Of those with positive RNA results, 389 (70.7%) received 
genotyping. Genotype 1 was most commonly identified (76.3%), followed by genotype 2 
(8.7%), genotype 5 (5.9%), genotype 3 (4.9%), and genotype 4 (1.0%). Of all anti-HCV+ 
patients, 133 (11.9%) were identified as infected with HIV.
Among the 133 anti-HCV+ patients with positive HIV status, 77.4% (n=103) were tested for 
HCV RNA to establish HCV infection. By contrast, 66.7% (n=654/980) of anti-HCV+ 
patients with negative HIV status received HCV RNA testing. After multivariable 
adjustment, the odds of receiving HCV RNA testing were nearly twice as high among anti-
HCV+ patients who were HIV infected compared with anti-HCV+ patients who were HIV 
negative (AOR=1.9, 95% CI=1.2, 3.0) (Table 2). Similarly, patients with a history of 
elevated ALT were almost twice as likely to receive HCV RNA testing (AOR=1.9, 95% 
CI=1.4, 2.4) compared with patients with normal/unknown ALT levels. Additionally, black 
race was marginally associated with decreased odds of receiving HCV RNA testing 
(AOR=0.7, 95% CI=0.5, 1.0). Gender, birth cohort, marital status, and IDU history were not 
independently associated with receipt of HCV RNA testing (Table 2).
Discussion
Testing for HCV RNA to determine active HCV infection is a necessary step to ensure 
accurate diagnosis of HCV and appropriate care and treatment for patients, especially given 
the availability of treatment with high cure rates.16,28,29 This analysis indicates that anti-
HCV+ patients who are also HIV positive are more likely to be tested for evidence of HCV 
viremia, compared with their HIV-negative counterparts. This finding may reflect routine 
clinical practice at the four healthcare systems from which patients were drawn for this 
study; it is reasonable to think that a physician with knowledge of a patient’s HIV-positive 
status would be more aware of the importance of confirming active HCV-infection status in 
an anti-HCV+ patient, and therefore would be more likely to request HCV RNA testing.22 
HIV-positive patients are also more likely to be in the care of infectious disease specialists, 
who may be more likely to recommend HCV RNA testing to establish current infection and 
seek treatment.
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The observation that patients with a history of elevated ALT levels have greater odds of 
receiving HCV RNA testing supports results from earlier studies,22,24 and may be indicative 
of healthcare provider knowledge of the high correlation between persistently elevated ALT 
levels and the probability of liver disease.17,30–32 The association between black race and 
lower odds of receiving HCV RNA testing may be confounded by lower levels of healthcare 
access among blacks33,34 and should be interpreted with caution, in part owing to the 
inability to adjust for socioeconomic measures (e.g., insurance type).
Limitations
This study has several limitations. First, although HCV RNA testing is only one component 
of the continuum of care,22,35 no data for other measures of HCV care were available. 
Second, data on history of blood transfusion, an important route of HCV transmission 
among older adults, were unavailable. Third, HCV RNA testing performed outside 
participating health systems may not have been captured. Fourth, cross-sectional analysis of 
the data limits the ability to assess temporal associations between independent risk factors 
and outcomes; for example, HIV testing may have occurred before or after HCV RNA 
testing. Finally, no distinction was made between current and past IDU. However, because 
of recall bias, past IDU (versus current use) is less likely to be reflected in an EMR.
Conclusions
These findings suggest that HIV infection status is independently associated with the 
likelihood of receiving HCV RNA testing following an anti-HCV+ test result. However, 
26% of HIV-positive and 33% of HIV-negative patients did not receive HCV RNA testing 
to establish active HCV infection. HCV RNA testing following an anti-HCV+ result should 
be conducted for all anti-HCV+ people to facilitate access to appropriate care and treatment 
for those with active HCV infection.
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Table 1
Characteristics of HCV Antibody Positive Patients, 2005–2010
N=1,115 Number of patients, n (%) a
Age, median (IQR) 52 (45–57)
Birth cohort
 Born before 1945 90 (8.1)
 Born 1945–1965 829 (74.3)
 Born after 1965 196 (17.6)
Gender
 Male 686 (61.5)
 Female 429 (38.5)
Marital statusb
 Married 319 (28.6)
 Widowed/divorced 164 (14.7)
 Never married 632 (56.6)
Race/ethnicityb
 White 330 (29.6)
 Black 574 (51.5)
 Hispanic 129 (11.5)
 Asian/Other 82 (7.4)
History of IDU
 Yes 361 (32.4)
 No 754 (67.6)
Elevated ALT
 Yes 690 (61.9)
 No 425 (38.1)
HIV Positive
 Yes 133 (11.9)
 No 982 (88.1)




Missing values for race/ethnicity(5.8%) and marital status (0.1%) were multiply imputed within the context of the larger dataset of 209,076 
patients.26













Yartel et al. Page 8
Table 2
Association Between HIV-Infection and Receipt of HCV-RNA Testing Following a Positive HCV Antibody 
Test Result
N=1,115 AORa (95% CI) p-value
HIV positive
 Yes 1.7 (1.1, 2.8) <0.01
 No 1.0 —
Birth cohort
 Born 1965 or before 1.0 —
 Born after 1965 1.3 (0.9, 1.9) 0.15
Gender
 Male 0.9 (0.7, 1.2) 0.57
 Female 1.0 —
Marital statusb
 Married 1.0 —
 Widowed/divorced 0.8 (0.6, 1.3) 0.47
 Never married 0.9 (0.6, 1.2) 0.37
Race/ethnicityb
 White 1.0 —
 Black 0.7 (0.5, 1.0) <0.05
 Other 0.9 (0.6, 1.3) 0.47
History of IDU
 Yes 0.9 (0.7, 1.3) 0.68
 No 1.0 —
Elevated ALT
 Yes 1.8 (1.4, 2.4) <0.001
 No 1.0 —
Note: Boldface indicates statistical significance (p<0.05).
ALT, alanine aminotransferase; HCV, hepatitis C virus; HCV-RNA, hepatitis C virus-ribonucleic acid; IDU, injection drug use.
a
Logistic regression model adjusted for all variables shown in table plus total number of visits.
b
Missing values for race/ethnicity (5.8%) and marital status (0.1%) were multiply imputed within the context of the larger dataset of 209,076 
patients.26
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